Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Yale University |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000247 |
The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.
Condition | Intervention | Phase |
---|---|---|
Substance-Related Disorders |
Drug: Flumazenil |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Rapid Benzodiazepine Detoxification Using Flumazenil |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, Connecticut | |
Yale University, Psychiatry | |
New Haven, Connecticut, United States, 06519 |
Principal Investigator: | Scott Woods, M.D. | Yale University |
Study ID Numbers: | NIDA-08265-2, R01-08265-2 |
Study First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000247 |
Health Authority: | United States: Federal Government |
Flumazenil Mental Disorders Substance-Related Disorders Disorders of Environmental Origin |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action GABA Modulators Physiological Effects of Drugs |
GABA Agents Protective Agents Pharmacologic Actions Antidotes |